1
|
Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, Valdagni R, Mantovani R, Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012; 19:1750-60. [PMID: 22555458 PMCID: PMC3469086 DOI: 10.1038/cdd.2012.56] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Revised: 03/27/2012] [Accepted: 03/30/2012] [Indexed: 12/21/2022] Open
Abstract
The basement membrane (BM) is a layer of specialized extracellular matrix that surrounds normal prostate glands and preserves tissue integrity. Lack or discontinuity of the BM is a prerequisite for tumor cell invasion into interstitial spaces, thus favoring metastasis. Therefore, BM maintenance represents a barrier against cancer development and progression. In the study, we show that miR-205 participates in a network involving ΔNp63α, which is essential for maintenance of the BM in prostate epithelium. At the molecular level, ΔNp63α is able to enhance miR-205 transcription by binding to its promoter, whereas the microRNA can post-transcriptionally limit the amount of ΔNp63α protein, mostly by affecting ΔNp63α proteasomal degradation rather than through a canonical miRNA/target interaction. Functionally, miR-205 is able to control the deposition of laminin-332 and its receptor integrin-β4. Hence, pathological loss of miR-205, as widely observed in prostate cancer, may favor tumorigenesis by creating discontinuities in the BM. Here we demonstrate that therapeutic replacement of miR-205 in prostate cancer (PCa) cells can restore BM deposition and 3D organization into normal-like acinar structures, thus hampering cancer progression.
Collapse
Affiliation(s)
- P Gandellini
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - V Profumo
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - A Casamichele
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - N Fenderico
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - S Borrelli
- Department of Biomolecular Sciences and
Biotechnology, University of Milan, Milan, Italy
| | - G Petrovich
- Department of Biomolecular Sciences and
Biotechnology, University of Milan, Milan, Italy
| | - G Santilli
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - M Callari
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - M Colecchia
- Department of Pathology, Fondazione IRCCS
Istituto Nazionale dei Tumori, Milan, Italy
| | - S Pozzi
- Department of Biomolecular Sciences and
Biotechnology, University of Milan, Milan, Italy
| | - M De Cesare
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - M Folini
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| | - R Valdagni
- Department of Radiotherapy, Fondazione IRCCS
Istituto Nazionale dei Tumori, Milan, Italy
- Prostate Program, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
| | - R Mantovani
- Department of Biomolecular Sciences and
Biotechnology, University of Milan, Milan, Italy
| | - N Zaffaroni
- Department of Experimental Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy
| |
Collapse
|